Compare DexCom, Inc. (DXCM) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Synopsys, Inc. — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Synopsys, Inc. trades at $509.99 (market cap $95.39B). The key difference: Synopsys, Inc. is far larger — about 3× DexCom, Inc.'s market cap, and DexCom, Inc. is more actively traded (3,607,070 versus 3,374,903). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Synopsys, Inc. for 71 Days on average.
| DXCM | SNPS | |
|---|---|---|
Market Cap | $31.86B | $95.39B |
Volume | 3,607,070 | 3,374,903 |
Sector | Health | Technology |
52-Week High | $92.34 | $534.56 |
52-Week Low | $54.84 | $367.70 |
Typical Hold Time | 62 Days | 71 Days |
Enterprise Value | $31.32B | $102.62B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Synopsys (SNPS) trades at $497.75, down 0.98% on the day, but maintains strong momentum with three consecutive quarterly earnings beats. The stock shows bullish technical signals with moving averages supporting upward trends, though RSI levels suggest potential overbought conditions. Recent AI partnerships with OpenAI and Amazon, along with raised 2027 guidance, have driven significant investor optimism and a 13% surge in early October 2026.
The outlook remains positive with 93% analyst buy ratings and a $572.54 consensus price target representing 15% upside. Key risks include high valuation multiples (P/E 86.87) and integration challenges from the Ansys acquisition. Revenue growth acceleration to $9.4B projected for 2026 and expanding AI-driven chip design opportunities support the bullish case, though investors should monitor execution on ambitious growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
